Examkin

Soru

Zorluk: OrtaRheumatology and Immunology

A 62-year-old man comes to the clinic because of severe, excruciating pain in his right great toe that began abruptly overnight. He cannot bear weight on his right foot or tolerate the bedsheets touching his toe. His past medical history is significant for hypertension, type 2 diabetes mellitus, and stage 4 chronic kidney disease. Current medications include amlodipine, insulin glargine, and lisinopril. His temperature is 37.6°C (99.7°F), blood pressure is 135/85 mmHg, and pulse is 92/min. Physical examination reveals a markedly erythematous, swollen, warm, and exquisitely tender right first metatarsophalangeal joint. Range of motion is severely limited due to pain. Laboratory studies show a serum creatinine level of 2.6 mg/dL (baseline 2.5 mg/dL) and a serum uric acid level of 5.8 mg/dL (normal: 4.0-8.5 mg/dL). Joint aspiration yields fluid with a leukocyte count of 35,000/mm³ and negatively birefringent, needle-shaped crystals. Gram stain shows no organisms. Which of the following is the most appropriate next step in management?

  1. Administration of intra-articular glucocorticoidsCevap
  2. B
    Administration of oral indomethacin
  3. C
    Initiation of oral allopurinol
  4. D
    Administration of intravenous vancomycin and ceftriaxone
  5. E
    Measurement of 24-hour urine uric acid excretion

Cevap

Administration of intra-articular glucocorticoids
The correct answer is the administration of intra-articular glucocorticoids. This patient presents with classic signs of an acute gout flare, specifically podagra (acute monoarthritis of the first metatarsophalangeal joint). The diagnosis is definitively confirmed by the presence of negatively birefringent, needle-shaped monosodium urate crystals in the synovial fluid. Standard first-line therapies for an acute gout attack include NSAIDs, colchicine, and glucocorticoids. However, this patient has stage 4 chronic kidney disease (CKD). NSAIDs are strictly contraindicated in severe CKD because they inhibit prostaglandin synthesis, leading to afferent arteriolar vasoconstriction and potentially severe acute kidney injury. Colchicine must also be avoided or heavily dose-reduced in advanced renal impairment due to the high risk of fatal neuromyopathy and bone marrow suppression. Therefore, glucocorticoids are the safest option. Because this is a monoarticular flare, an intra-articular injection of glucocorticoids is preferred over systemic administration. This localized approach provides rapid relief while minimizing systemic side effects, which is particularly advantageous for this patient who also has type 2 diabetes mellitus, as systemic steroids can precipitate severe hyperglycemia.

Adım Adım Çözüm

1
Identify the patient's primary diagnosis based on the clinical presentation and diagnostic studies.
The patient has an acute monoarthritis of the first metatarsophalangeal joint (podagra) with negatively birefringent crystals in the synovial fluid, confirming an acute gout flare.
Establishing the correct diagnosis is essential before determining the appropriate treatment pathway.
2
Evaluate the patient's medical history and current organ function to identify any contraindications to standard therapies.
The patient has stage 4 chronic kidney disease with a significantly elevated serum creatinine of 2.6 mg/dL.
First-line treatments for acute gout include NSAIDs, colchicine, and glucocorticoids. The choice depends heavily on patient comorbidities.
3
Select the safest and most effective targeted therapy based on the comorbidities.
NSAIDs and colchicine are contraindicated or highly problematic in severe chronic kidney disease. Intra-articular glucocorticoids are safe, avoid systemic side effects (especially important given his diabetes), and effectively treat monoarticular flares.
Intra-articular glucocorticoid injection provides direct local anti-inflammatory action without the risk of systemic nephrotoxicity.

Anahtar Kavram

In patients with an acute gout flare and severe chronic kidney disease, nonsteroidal anti-inflammatory drugs (NSAIDs) and colchicine are typically contraindicated, making intra-articular or systemic glucocorticoids the safest and most appropriate first-line treatment.
Tahmini Süre:1m 0s
Bu soruyu puanla

Konular

Rheumatology and Immunology

Bu konudan daha fazla soru